400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / GPCR/G Protein / Glucagon Receptor / MK 0893
CAS No.: 870823-12-4
MK 0893 is a potent, selective glucagon receptor antagonist with IC50 of 6.6 nM, showing > 200 fold selectivity for GIPR, PAC1, GLP-1R, VPAC1 and VPAC2.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02012166 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | - |
NCT00631488 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
NCT00479466 | - | - | Terminated(Sufficient data reg... more >>arding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy) Collapse << | - | - |
实验方案
技术信息
CAS号 | 870823-12-4 | 储存条件 |
|
|
分子式 | C32H27Cl2N3O4 | 运输 | 蓝冰 | |
分子量 | 588.48 | 别名 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02012166 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | - |
NCT00631488 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
NCT00479466 | - | - | Terminated(Sufficient data reg... more >>arding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy) Collapse << | - | - |
NCT00479466 | Diabetes Mellitus, Type 2 | Phase 2 | Terminated(Sufficient data reg... more >>arding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy) Collapse << | - | - |
NCT00902161 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | - |
NCT00902161 | - | - | Completed | - | - |
NCT02004886 | - | - | Completed | - | - |
NCT00631488 | - | - | Completed | - | - |
NCT02004886 | Type 2 Diabetes Mellitus | Phase 2 | Completed | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网